Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900924 | 0.77 | FAAH (0.46) | HPGDSMN1; SMN2KMT2ATDP1FABP7 | |
| SCHEMBL3221490 | 0.76 | MIF (0.76) | POLBELANEMIFKMT2APKM | |
| SCHEMBL3850429 | 0.76 | RAB9A (0.60) | POLBSMN1; SMN2RAB9AEPHX2THRB | |
| SCHEMBL3221487 | 0.76 | MIF (0.76) | POLBELANEMIFKMT2APKM | |
| SCHEMBL11201619 | 0.74 | SMN1; SMN2 (0.48) | ELANEHPGDSMN1; SMN2KMT2ATDP1 | |
| SCHEMBL11963969 | 0.73 | MIF (0.75) | POLBELANEMIFSMN1; SMN2PKM | |
| SCHEMBL234456 | 0.73 | POLB (0.76) | POLBELANEHPGDSMN1; SMN2HTT | |
| SCHEMBL10911289 | 0.73 | POLB (0.76) | POLBELANEHPGDSMN1; SMN2HTT | |
| SCHEMBL10958586 | 0.73 | POLB (0.76) | POLBELANEHPGDSMN1; SMN2HTT | |
| SCHEMBL10949493 | 0.73 | POLB (0.76) | POLBELANEHPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | POLB 4436/4885ELANE 388/4885HPGD 3989/4885 |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | POLB 2457/4885ELANE 4148/4885HPGD 380/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | POLB 3397/4885ELANE 298/4885HPGD 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.